FDA Approves - New Antidepressant August 2022

New antidepressant Auvelity from Axsome Therapeutics is FDA approved for use in Major Depression Disorder. 

It is unique for its mechanism of action - as it is the first and at this time only medication that works by blocking NMDA receptors (NMDA receptor antagonist). The drug is the combination of two already existing medications.

 Dextromethorphan 45mg in combinations with Bupropion 105mg.

Dextromethorphan acts to antagonize NMDA receptor and Sigma 1 Receptor agonism.  While Bupropion blocks reuptake of Norepinephrine and Dopamine.

- Aug 2022